Cyterix Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cyterix Pharmaceuticals Inc.
Cyterix Pharmaceuticals Inc. thinks it has found a way to safely increase the maximum tolerated dose of gemcitabine, a widely used cancer drug. The prodrugs that Cyterix is developing are meant to be activated by specific variants within a huge family of enzymes all classified as cytochrome P450 enzymes.
Changing dynamics in oncology, from increasing availability of generics to payors' unapologetic cost-consciousness, are influencing companies of all sizes. Recent ch biostart-up financings show support is available to those positioned to deliver value for money. In this issue we profile Cyterix Pharmaceuticals, Polaris Group, Tesaro, Tocagen, Tragara Pharmaceuticals and VentiRx Pharmaceuticals.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
This Month's Profile Groups: Upheaval and Opportunity Reshape The Oncology Market features profiles of Cyterix Pharmaceuticals, Polaris, Tocagen, Tragara Pharmaceuticals and VentiRx Pharmaceuticals. Patient-Centric Devices Promise Cost-Efficient Wound Care features profiles of Reapplix, Spiracur and Wound Solutions. Plus these Start-Ups Across Health Care: Cebix, Jan Medical, Life Recovery Systems, Respira and SeptRx.